



Dr. Yulia Lin, Pre-operative Patient Blood Management

What is patient blood management?

- Patient-centered and organized approach in which the entire health care team coordinates efforts to improve results by managing and preserving a patient's own blood
 - 1. Treat Anemia
 - 2. Minimize blood loss
 - 3. Appropriate use of blood

Why is treating preoperative anemia so important?

- 1. Preop anemia is associated with increased mortality
- 2. Preop anemia is potentially modifiable (both as a risk factor and a treatable condition)
- 3. Preop anemia is common ~ 1/3 of pts going for surgery have anemia!
- 4. Preop anemia is associated with transfusion
- 5. Transfusion is a bad outcome
- 6. The donor supply is precious resource

How to treat preoperative anemia?

- Autologous blood
 - o Only to be used for patients with very rare blood type, for whom blood donors cannot be easily found
- Diagnose iron deficiency anemia
 - Check the CBC 4-6 weeks preop.
 - For high blood loss major surgery, the target is preop Hb if 130 g/L in both males and females
 - Iron deficiency anemia is defined as:
 - Ferritin < 30 mcg/L; or
 - Ferritin < 100 mcg/L AND transferrin saturation < 20%
 - Low iron stores defined as:
 - Ferritin < 100 mcg/L</p>
- Treat iron deficiency anemia
 - Always remember to identify the cause (Bleeding is the most common source)
 - Start with oral iron salts when possible
 - Consider iv iron when
 - Oral iron is not tolerated or ineffective
 - Short time to surgery < 4-6 weeks
 - Severe anemia, e.g. Hb < 100 g/L
 - Active bleeding
- Consider the role of erythropoiesis stimulating agents in
 - o Patients with religious objections to blood
 - o Patients with multiple alloantibodies where it is difficult to find blood
 - o Patients with high blood loss surgery (although cost-effectiveness less clear here)

TRANSFUSION CAMP RESOURCES ARE DEVELOPED BY TRANSFUSION CAMP FACULTY FOR EDUCATIONAL PURPOSES ONLY. THE RESOURCES <u>MUST NOT BE USED OR DISTRIBUTED OUTSIDE OF TRANSFUSION CAMP</u> WITHOUT THE CONSENT OF THE TRANSFUSION CAMP ORGANIZERS. THE MATERIALS ARE NOT INTENDED TO BE A SUBSTITUTE FOR THE ADVICE OF A PHYSICIAN AND SHOULD BE ASSESSED IN THE CONTEXT OF THE APPLICABLE MEDICAL, LEGAL AND ETHICAL REQUIREMENTS IN ANY INDIVIDUAL CASE. PROVIDE FEEDBACK ON TRANSFUSION CAMP RESOURCES OR ENQUIRE ABOUT TRANSFUSION CAMP BY CONTACTING TRANSFUSIONCAMP@BLOOD.CA.





Dr. Natasha Rupani, Dr. Michelle Sholzberg - Congenital Coag – VWD, Hemophilia

Hemostasis Simplified



The bleeding history if the most important TEST of hemostasis, using a validated bleeding assessment tool (BAT).

A normal PT and aPTT does not rule out a bleeding disorder.

Von Willebrand Disease

Diagnosis: 1) Bleeding Symptoms, 2) Family History, 3) Laboratory Results

MucocutaneousMuHeavy menstrual bleeding(TyEpistaxisBruising	Iusculoskeletal ype 2N, 3) Hemarthrosis	Call Hematology/Transfusion Medicine Principle of treatment: Increase or replace VWF
 Excessive bleeding from minor wounds GI bleeding Oral cavity/post-dental procedure Post-operative Post-partum 	Soft tissue, muscle hematomas	 DDAVP (Desmopressin) VWF:FVIII Concentrate (Humate P, Wilate) Adjunctive anti-fibrinolytic agent (TXA)
Hemophilias: Factor 9 Int Hemophilia B • Factor IX deficiency • 1 in 30,000 males	9 Factor 8 htrinsic Xase complex Hemophilia A y • Factor VIII deficiency • 1 in 5,000 males	"Low VWF" • Mild/ moderate quantative trait Type 1 (1C) • 80% of cases ZA • Qualitative trait 2B • 20% of cases ZM • Severe quantative defect Type 3 • Severe quantative defect • 1 per million cases
 Bleeding Symptoms Musculoskeletal bleeding Hemarthrosis Intra-muscular hematoma Mouth bleeding, epistaxis Intracranial bleeding Bleeding with trauma, procedures, surgery Heavy menstrual bleeding (symptomatic carriers) 	Treatment Call Heman Principle of tre Factor VIII: Xyntha, Kovaltry, Nuwic Factor IX: Benefix, Rebinyn DDAVP (Desmopressin) – mild hem Adjunctiv	tology/Transfusion Medicine eatment: Replace deficient factor q, Adynovate, Jivi, hophilia (FVIII>10%) Non-factor therapies: Emicizumab • Avoid PCC – risk of thrombosis • Inhibitor present - rVIIa • No inhibitor – FVIII concentrate

Resources

- "Principles of Management of Urgent Bleeding in Hemophilia" developed by Dr. Jerry Teitel
- Blood Easy: Coagulation Simplified developed by ORBCoN
- <u>Illustrated Review of Bleeding Assessment Tools and Coagulation tests</u> (Elbaz, Sholzberg)

TRANSFUSION CAMP RESOURCES ARE DEVELOPED BY TRANSFUSION CAMP FACULTY FOR EDUCATIONAL PURPOSES ONLY. THE RESOURCES <u>MUST NOT BE USED OR DISTRIBUTED OUTSIDE OF TRANSFUSION CAMP</u> WITHOUT THE CONSENT OF THE TRANSFUSION CAMP ORGANIZERS. THE MATERIALS ARE NOT INTENDED TO BE A SUBSTITUTE FOR THE ADVICE OF A PHYSICIAN AND SHOULD BE ASSESSED IN THE CONTEXT OF THE APPLICABLE MEDICAL, LEGAL AND ETHICAL REQUIREMENTS IN ANY INDIVIDUAL CASE. PROVIDE FEEDBACK ON TRANSFUSION CAMP RESOURCES OR ENQUIRE ABOUT TRANSFUSION CAMP BY CONTACTING TRANSFUSIONCAMP@BLOOD.CA.